Monitor for PDUFA decision on January 30, 2027. Approval would expand Joenja's addressable pediatric population and support revenue growth trajectory. Near-term catalyst is binary with significant upside if approved.
Price Chart
Executive Summary
Pharming announced FDA acceptance and Priority Review of its sNDA for lower doses of Joenja (leniolisib) to treat children aged 4+ with APDS weighing 13-27 kg. The PDUFA target action date is January 30, 2027. This expands the addressable pediatric population following the September 2026 approval for children weighing at least 27 kg.
Key Facts
- FDA accepted sNDA for lower doses of Joenja for children aged 4+ with APDS weighing 13-27 kg
- Granted Priority Review with PDUFA target action date of January 30, 2027
- sNDA supported by positive Phase III open-label study showing reduced lymphadenopathy and increased naive B cells over 12 weeks
- Follows recent FDA approval (September 2026) of Joenja for children aged 4-11 weighing at least 27 kg
- Joenja is the first and only targeted treatment for APDS
Financial Impact
Expansion of addressable pediatric APDS population by adding children weighing 13-27 kg; no financial figures disclosed in filing
Risk Factors
- FDA may issue a Complete Response Letter (CRL) or require additional data
- Commercial uptake in the lower-weight pediatric segment may be slower than expected
- Competition from other PI3K inhibitors or emerging APDS therapies
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000041 |
| Document: 0001828316-26-000041-index-headers.html | 0001828316-26-000041 |
| Document: 0001828316-26-000041-index.html | 0001828316-26-000041 |
| Document: 0001828316-26-000041.txt | 0001828316-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $11.55 | awaiting T+1 | awaiting T+1 | $11.87 (+2.77%) |
Oct 27, 2026 1d ago | Press Release | $11.55 | awaiting T+1 | awaiting T+1 | $11.87 (+2.77%) |
Oct 22, 2026 5d ago | 6-K | $10.67 $11.20 | ▲ +4.97% | ▲ +5.49% | $11.87 (+11.25%) |
Oct 14, 2026 13d ago | 6-K | $9.64 $9.63 | ▼ −0.10% | ▼ −0.39% | $11.87 (+23.13%) |
Sep 29, 2026 28d ago | 6-K | $10.01 $9.99 | ▲ +0.20% | ▼ −0.01% | $11.87 (−18.58%) |
Sep 29, 2026 29d ago | Press Release | $10.01 $9.99 | ▲ +0.20% | ▼ −0.01% | $11.87 (−18.58%) |
Sep 25, 2026 4w ago | 6-K | $10.46 $10.52 | ▲ +0.57% | ▲ +1.32% | $11.87 (+13.48%) |
Sep 25, 2026 4w ago | Press Release | $10.46 $10.52 | ▲ +0.57% | ▲ +1.32% | $11.87 (+13.48%) |
Sep 22, 2026 5w ago | 6-K | $11.26 $10.77 | ▼ −4.35% | ▼ −3.63% | $11.87 (+5.42%) |
Sep 11, 2026 6w ago | 6-K | $11.21 $10.82 | ▼ −3.48% | ▼ −3.03% | $11.87 (+5.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers